Vaccinations for the traveling adult solid organ transplant recipient (excluding hematopoietic stem cell transplant recipients);Vaccinations du voyageur adulte transplanté d'organes (à l'exclusion des receveurs de cellules souches hématopoïétiques)

Medecine et Maladies Infectieuses

Volumn 39, Issue 4, 2009, Pages 225-233

  Wyplosz, B ^a   Van der Vliet, D ^b   Consigny, P H ^c   Calmus, Y ^d   Mamzer Bruneel, M F ^e   Guillemain, R ^f   Malvy, D ^g   Samuel, D ^a   Vittecoq, D ^a   Launay, O ^b  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR   (France)

^d Hôpital Saint André ^*  (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Immunocompromised host; Solid organ transplant recipient; Traveller; Vaccination

Indexed keywords

AZATHIOPRINE; BCG VACCINE; CHICKENPOX VACCINE; CYCLOSPORIN A; DIPHTHERIA PERTUSSIS TETANUS VACCINE; EVEROLIMUS; HEPATITIS A VACCINE; HEPATITIS B VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; RAPAMYCIN; TACROLIMUS; VARICELLA ZOSTER VACCINE; YELLOW FEVER VACCINE;

BCG VACCINATION; CHICKENPOX; CHOLERA; COMORBIDITY; DIPHTHERIA; DISEASE COURSE; EPIDEMIC ENCEPHALITIS; EPIDEMIC MENINGITIS; FOLLOW UP; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; MEASLES; MUMPS; ORGAN TRANSPLANTATION; POLIOMYELITIS; RABIES; REVIEW; RUBELLA; STREPTOCOCCUS INFECTION; TETANUS; TICK BORNE ENCEPHALITIS; TRAVEL; TREATMENT CONTRAINDICATION; TYPHOID FEVER; VACCINATION; YELLOW FEVER;

EID: 67349113158     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2008.11.006     Document Type: Review

References (63)

1. Agence de la biomédecine. Rapport annuel : bilan des activités de l'Agence de la biomédecine 2007. Saint-Denis la Plaine : Agence de biomédecine ; 2007.
2. Boggild A., Sano M., Humar A., Gilman M., Salit I., and Kain K. Travel patterns and risk behavior in solid organ transplant recipients. J Travel Med 11 (2004) 37-43
3. Duchini A., Goss J.A., Karpen S., and Pockros P.J. Vaccinations for adult solid organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 16 (2003) 357-364
4. Stark K., Gunther M., Schonfeld C., Tullius S.G., and Bienzle U. Immunisations in solid organ transplant recipients. Lancet 359 (2002) 957-965
5. Committee to Advise on TropicalMedicine and Travel (CATMAT). Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004;4:160-3.
6. Committee to advise on tropical medicine and travel. The immuncompromised traveller. An advisory committee statement. Can Commun Dis Rep 33 (2007) 1-24
7. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. 10th ed. (2007), Public Health Foundation, Washington DC
8. Centers for Disease Control and Prevention. Health information for international travel 2008 (2007), US Department of Health and Human Services, Public Health Service, Atlanta
9. Haut Conseil de la santé publique. Calendrier vaccinal 2008. BEH 16-17 (2007) 129-148
10. Avery R.K., and Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 8 (2008) 9-14
11. Knoop C., Haverich A., and Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 23 (2004) 159-171
12. Lindenfeld J., Miller G.G., Shakar S.F., Zolty R., Lowes B.D., Wolfel E.E., et al. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation 110 (2004) 3734-3740
13. Rosen H.R. Transplantation immunology: what the clinician needs to know for immunotherapy. Gastroenterology 134 (2008) 1789-1801
14. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med 351 (2004) 2715-2729
15. Goldfarb N.S., Avery R.K., Goormastic M., Mehta A.C., Schilz R., Smedira N., et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 71 (2001) 242-246
16. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 6 (2007) 699-710
17. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 (2007) 580-589
18. Bienzle U., Gunther M., Neuhaus R., Vandepapeliere P., Vollmar J., Lun A., et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 38 (2003) 811-819
19. Magnani G., Falchetti E., Pollini G., Reggiani L.B., Grigioni F., Coccolo F., et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 24 (2005) 588-592
20. Schrauder A., Henke-Gendo C., Seidemann K., Sasse M., Cario G., Moericke A., et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet 369 (2007) 1232
21. Kengsakul K., Sathirapongsasuti K., and Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85 (2002) 131-134
22. Amanna I.J., Carlson N.E., and Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357 (2007) 1903-1915
23. Direction générale de la santé. Comité technique des vaccinations. Guide des Vaccinations: INPES ; 2008.
24. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358 (2001) 98-104
25. Monath T.P., and Cetron M.S. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 34 (2002) 1369-1378
26. Barwick R. History of thymoma and yellow fever vaccination. Lancet 364 (2004) 936
27. Legros F., Leroy J.-P., Massy N., Saluzzo J.-F., de Gentile L., and Teuwen D. Fièvre jaune, épidémiologie et prévention vaccinale du voyageur. BEH 25-26 (2007) 236-238
28. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 22 (2004) 2103-2105
29. Khan S., Erlichman J., and Rand E.B. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 10 (2006) 78-82
30. Weinberg A., Horslen S.P., Kaufman S.S., Jesser R., Devoll-Zabrocki A., Fleckten B.L., et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 6 (2006) 565-568
31. Geel A.L., Landman T.S., Kal J.A., van Doomum G.J., and Weimar W. Varicella zoster virus serostatus before and after kidney transplantation, and vaccination of adult kidney transplant candidates. Transplant Proc 38 (2006) 3418-3419
32. Scharpé J., Evenepoel P., Maes B., Bammens B., Claes K., Osterhaus A., et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2 (2008) 332-337
33. White-Williams C., Brown R., Kirklin J., St Clair K., Keck S., O'Donnell J., et al. Improving clinical practice: should we give influenza vaccinations to heart transplant patients?. J Heart Lung Transplant 25 (2006) 320-323
34. Neal S., and Efstratiou A. DIPNET: establishment of a dedicated surveillance network for diphtheria in Europe. Euro Surveill 12 (2007) E9-E10
35. Global polio eradication initiative.(Accessed at http://www.polioeradication.org/). 09/12/08.
36. Imported vaccine-associated paralytic poliomyelitis-United States, 2005. MMWR Morb Mortal Wkly Rep 2006;55:97-9.
37. Huzly D., Neifer S., Reinke P., Schroder K., Schonfeld C., Hofmann T., et al. Routine immunizations in adult renal transplant recipients. Transplantation 63 (1997) 839-845
38. Roche B., and Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 10 (2004) S74-S85
39. Sanchez-Fructuoso A.I., Prats D., Naranjo P., Fernandez-Perez C., Gonzalez M.J., Mariano A., et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation 69 (2000) 436-439
40. Rosenau J., Hooman N., Hadem J., Rifai K., Bahr M.J., Philipp G., et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 13 (2007) 367-373
41. Lefebure A.F., Verpooten G.A., Couttenye M.M., and De Broe M.E. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine 11 (1993) 397-399
42. Feuerhake A., Muller R., Lauchart W., Pichlmayr R., and Schmidt F.W. HBV-vaccination in recipients of kidney allografts. Vaccine 2 (1984) 255-256
43. Nevens F., Zuckerman J.N., Burroughs A.K., Jung M.C., Bayas J.M., Kallinowski B., et al. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. Liver Transpl 12 (2006) 1489-1495
44. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 355 (2000) 561-565
45. Duchini A., Hendry R.M., Redfield D.C., and Pockros P.J. Influenza infection in patients before and after liver transplantation. Liver Transpl 6 (2000) 531-542
46. Vilchez R.A., Fung J., and Kusne S. The pathogenesis and management of influenza virus infection in organ transplant recipients. Transpl Infect Dis 4 (2002) 177-182
47. Vilchez R.A., McCurry K., Dauber J., Lacono A., Griffith B., Fung J., et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2 (2002) 287-291
48. Burbach G., Bienzle U., Stark K., Rayes N., Neuhaus R., Serke S., et al. Influenza vaccination in liver transplant recipients. Transplantation 67 (1999) 753-755
49. Blumberg E.A., Albano C., Pruett T., Isaacs R., Fitzpatrick J., Bergin J., et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 22 (1996) 295-302
50. Versluis D.J., Beyer W.E., Masurel N., Wenting G.J., and Weimar W. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 42 (1986) 376-379
51. Mazzone P.J., Mossad S.B., Mawhorter S.D., Mehta A.C., Schilz R.J., and Maurer J.R. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J 18 (2001) 971-976
52. Kumar D., Welsh B., Siegal D., Chen M.H., and Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients: three year follow-up of a randomized trial. Am J Transplant 7 (2007) 633-638
53. Linnemann Jr. C.C., and First M.R. Risk of pneumococcal infections in renal transplant patients. JAMA 241 (1979) 2619-2621
54. Amber I.J., Gilbert E.M., Schiffman G., and Jacobson J.A. Increased risk of pneumococcal infections in cardiac transplant recipients. Transplantation 49 (1990) 122-125
55. Sever M.S., Yildiz A., Eraksoy H., Badur S., Yuksel-Onel D., Gorcin B., et al. Immune response to Haemophilus influenzae type B vaccination in renal transplant recipients with well-functioning allografts. Nephron 81 (1999) 55-59
56. Haut-conseil de la santé publique, and Dgdls. Recommandations sanitaires pour les voyageurs 2008 (à l'attention des professionnels de santé). BEH 25-26 (2008) 225-236
57. Keeffe E.B. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?. Am J Gastroenterol 90 (1995) 201-205
58. Stark K., Gunther M., Neuhaus R., Reinke P., Schroder K., Linnig S., et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis 180 (1999) 2014-2017
59. Arslan M., Wiesner R.H., Poterucha J.J., and Zein N.N. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 72 (2001) 272-276
60. Dumot J.A., Barnes D.S., Younossi Z., Gordon S.M., Avery R.K., Domen R.E., et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 94 (1999) 1601-1604
61. Gunther M., Stark K., Neuhaus R., Reinke P., Schroder K., and Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 71 (2001) 477-479
62. Dengler T.J., Zimmermann R., Meyer J., Sack F.U., Girgsdies O., and Kubler W.E. Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients. Vaccine 17 (1999) 867-874
63. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 370 (2007) 1847-1853